IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
16.59
-0.47 (-2.73%)
Mar 31, 2025, 10:47 AM EDT - Market open
IDEAYA Biosciences Revenue
In the year 2024, IDEAYA Biosciences had annual revenue of $7.00M, down -70.07%. IDEAYA Biosciences had revenue of $7.00M in the quarter ending December 31, 2024, with 78.48% growth.
Revenue (ttm)
$7.00M
Revenue Growth
-70.07%
P/S Ratio
198.95
Revenue / Employee
$53,435
Employees
131
Market Cap
1.45B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IDYA News
- 4 hours ago - IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PRNewsWire
- 3 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 days ago - IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PRNewsWire
- 6 weeks ago - IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 6 weeks ago - IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PRNewsWire
- 6 weeks ago - Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming - Seeking Alpha
- 7 weeks ago - IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PRNewsWire